{
  "id": 6825102,
  "title": "Edwards Lifesciences CVP Daniel Lippis sells $54,168 in stock",
  "url": "https://urgent.news/2026/09/11/edwards-lifesciences-cvp-daniel-lippis-sells-54-168-in-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-11T23:45:57.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/edwards-lifesciences-cvp-daniel-lippis-sells-54168-in-stock-93CH-4898565"
  },
  "original_language": "en",
  "account": null,
  "summary": "Edwards Lifesciences Corp (EW) insider Daniel J. Lippis, the Chief Validation Officer for TAVR, sold 619 shares of the company's common stock on September 11, 2026, for a total value of $54,168. The sale price of $87.51 per share was higher than the current stock price of $84.37, while analysts suggest the shares are fairly valued at this level. Simultaneously, Lippis bought 619 shares using employee stock options, acquiring them at an exercise price of $72.68 per share, totaling $44,988. Following these transactions, Lippis now holds 40,033.9103 shares of Edwards Lifesciences common stock. All share transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by Lippis on February 13, 2026.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Hinge Health CEO Daniel Perez disposes of $22.3 million in company stock",
        "url": "https://urgent.news/2026/09/12/hinge-health-ceo-daniel-perez-disposes-of-22-3-million-in-company",
        "published": "2026-09-12T02:31:02.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}